Latest glioblastoma multiforme Stories

BETHESDA, Md., Aug. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the Company's ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company also announced that a substantial number of additional sites are in process. With the 12 sites already...

A single compound with dual function "“ the ability to deliver a diagnostic and therapeutic agent "“ may one day be used to enhance the diagnosis, imaging and treatment of brain tumors, according to findings from Virginia Commonwealth University and Virginia Tech.Glioblastomas are the most common and aggressive brain tumor in humans, with a high rate of relapse. These tumor cells often extend beyond the well-defined tumor margins making it extremely difficult for clinicians and...

Research targets malignant glioma stem cellsCleveland Clinic researchers have identified a cellular pathway that cancer stem cells use to promote tumor growth in malignant glioma, an aggressive brain tumor. The research "“ published in the July 8 issue of Cell "“ also found that existing medications block this cancer-promoting pathway and delay glioma growth in animal models, suggesting a new treatment option for these often fatal brain tumors.Malignant gliomas account for more than half...

BETHESDA, Md., July 8, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) ("NWBT") announced today a $4.55 million equity investment on June 28, 2011, by The Richard M. Schulze Family Foundation (the "Foundation"). The sale of newly issued common stock of the Company to the Foundation follows the investment of $3 million, on May 31, 2011, by investment funds managed by Whitebox Advisors, a multi-billion dollar hedge fund group headquartered in Minneapolis, Minnesota...

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer. In the July 8th issue of the journal Cell, a Cell Press publication, a new study identifies an enzyme found in glioma stem cells that allows them to grow and seed tumors. Importantly, normal stem cells, including those in the brain, don't appear to share that same dependency."When thinking about therapeutics [targeting cancer stem cells], you have to be careful that you...

The drug ICT-107 targets 6 antigens found in brain tumors and 3 found in cancer stem cells, prolonging survival in patients with newly diagnosed glioblastoma multiformeAn experimental vaccine developed by researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute targets overactive antigens in highly aggressive brain tumors and improves length of survival in newly diagnosed patients, according to new data that was presented in a poster session at the 47th Annual...

BRAINTREE, Mass., June 15, 2011 /PRNewswire/ -- Herman Lowe, who has been battling terminal brain cancer, Glioblastoma, for over two years, has written a free online book, "Brain Cancer: Beating the Odds" about his journey and what he has done to try to help others with this deadly disease. Lowe, a semi-retired clinical psychologist, explains in the book why he is convinced that the use of cell phones has played a significant role in his contracting brain cancer. While he knows that...

SAN DIEGO, June 7, 2011 /PRNewswire/ -- Tocagen Inc. today announced the company is enrolling patients with recurrent high grade glioma, such as those with glioblastoma multiforme (GBM, Grade 4), in its first-in-human clinical trial of Toca 511. The multicenter, open-label study is evaluating the safety and tolerability of single ascending doses of Toca 511 administered intratumorally followed by cycles of the prodrug 5-fluorocytosine (5-FC) in patients who have failed prior surgery and...

CHICAGO, June 6, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: CTIC) announced encouraging interim results of a phase II clinical study of OPAXIO (paclitaxel poliglumex, PPX) combined with temozolomide ("TMZ") and radiotherapy ("RT") in patients with newly diagnosed high-grade malignant brain tumors (astrocytomas and glioblastomas). While not a randomized trial, treatment with OPAXIO, TMZ and RT resulted in a median progression free survival (PFS) of 13.5...

BETHESDA, Md., June 5, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further funding on fixed, specified and favorable terms, at such times and in such amounts as the Company chooses. This series of financing arrangements will provide a strong financial foundation for completion of the Company's ongoing...